Potentiator Ivacaftor Abrogates Pharmacological Correction of ΔF508 CFTR in Cystic Fibrosis

Cystic Fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR). Newly developed “correctors” such as lumacaftor (VX-809) that improve CFTR maturation and trafficking and “potentiators” such as ivacaftor (VX-770) that enhance channel activity may provide important ad...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Transl Med
Hlavní autoři: Cholon, Deborah M., Quinney, Nancy L., Fulcher, M. Leslie, Esther, Charles R., Das, Jhuma, Dokholyan, Nikolay V., Randell, Scott H., Boucher, Richard C., Gentzsch, Martina
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4272825/
https://ncbi.nlm.nih.gov/pubmed/25101886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3008680
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky